Physician profile
Anthony Tran
NPI 1275594897
$6,278.28
in general payments reported to CMS, 2019-2025
27 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $1,930 · 2021: $223 · 2022: $2,370 · 2023: $673 · 2024: $382 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Consulting Fee: $200 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.95 |
| Consulting Fee | $200.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,545.80 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $693.20 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $292.56 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $266.00 | 2020-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $244.94 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $233.80 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $192.94 | 2022-2024 | Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $117.02 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $96.63 | 2019 | |
| Ani Pharmaceuticals, INC. | $83.26 | 2022-2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.08 | 2023-2025 | Jardiance |
| Genzyme Corporation | $58.11 | 2019 | |
| Edwards Lifesciences Corporation | $48.95 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $37.07 | 2021-2023 | Ozempic |
| Novartis Pharmaceuticals Corporation | $35.90 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.14 | 2023-2024 | Jardiance |
| Vifor Pharma, INC. | $34.45 | 2019-2021 | |
| Amgen INC. | $32.12 | 2022-2025 | Krystexxa |
| Aurinia Pharma U.S., INC. | $23.48 | 2021 | |
| Shire North American Group INC | $22.07 | 2019 | |
| Opko Pharmaceuticals, LLC | $17.98 | 2021 | |
| Vantive US Healthcare LLC | $17.81 | 2025 | Renal - Pd |
| Alexion Pharmaceuticals, INC. | $16.39 | 2019 | |
| Akebia Therapeutics INC | $14.83 | 2021 | |
| Genentech USA, INC. | $14.49 | 2022 | |
| Kyowa Kirin, INC. | $14.48 | 2023 | Crysvita |
| Cardiovascular Systems INC. | $10.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.